Collaboration project IBD model
MIMETAS, Galapagos, and University of Sheffield, to develop organ-on-a-chip model for Inflammatory Bowel Disease
Leiden, August 24, 2016. MIMETAS, Galapagos, (Euronext & NASDAQ: GLPG), and University of Sheffield, have embarked on a collaboration to develop an Inflammatory Bowel Disease (IBD) model in MIMETAS’ OrganoPlates®. IBD, covering both Crohn’s disease as well as ulcerative colitis, is an inflammatory condition of the gastrointestinal tract with loss of integrity of the intestinal barrier playing a key pathogenic role. Over 3.5 million suffer from the disease in Europe and the US, resulting in a global death toll of 51,000 in 2013.
The IBD disease model will be developed using human organoid technology, OrganoPlates® and CRISPR/Cas9 gene editing techniques. Recently, MIMETAS has presented small intestinal gut organoids in OrganoPlates® at the International Society for Stem Cell Research Conference ISSCR 2016 in San Francisco. “Our OrganoPlate® platform is ideally suited for tackling the IBD modeling problem, as it allows us to assess intestinal barrier function with high sensitivity under a wide range of conditions in parallel, including microbiome exposure and co-cultures.”, says Dr. Jos Joore, Managing Director of Mimetas, “As such, this project has a strong potential to lead to improved therapeutic options for IBD.”
The research work is partly backed by a 1 million euro EU contribution through the MIMIC project in collaboration with Dr. Kai Erdmann of the University of Sheffield (UK), who is an expert in membrane trafficking and signaling in polarized epithelia. “This consortium hits the ground running,”, says Erdmann, “as my group and MIMETAS are already collaborating in an EU project named BIOPOL, while MIMETAS and Galapagos have a long-standing collaboration.”